Extract
Over recent years, the field of breathomics has matured such that systematic reviews are not only viable, but considered important enough for disseminationviahigh impact clinical research journals such as theEuropean Respiratory Journal. Recently, we have seen accelerating interest in this exciting biomarker discovery platform with reviews covering topics such as paediatric asthma [1], lung infection [2, 3] and fibrotic lung diseases [4, 5]. For rapidly developing fields such as this, synoptic work provides important functions both for newcomers, by introducing and stimulating interest, but equally for established researcher teams, by highlighting both consistency and variability in findings across studies.
Abstract
Reports of potential biomarkers in breath are rapidly accumulating, such that systematic reviews are now feasible. We should now take stock and ensure every future study design is able to contribute a step forward towards future clinical application.http://bit.ly/2khqrWi
Footnotes
Conflict of interest: S.J Fowler reports personal fees for lectures and non-financial support for meeting attendance from AstraZeneca, grants and personal fees for lectures from Boehringer Ingelheim, personal fees for lectures from Novartis and Teva, personal fees for advisory board work from Chiesi, outside the submitted work.
利益冲突:P.J.斯德克已被Sci报告entific Advisor and having a formally inconsiderable interest in the start-up company Breathomix, a start-up producing eNoses and licensing a cloud application for data analysis, during the conduct of the study.
- ReceivedJuly 16, 2019.
- AcceptedAugust 27, 2019.
- Copyright ©ERS 2019